Aclys Bio develops precision antibodies using molecular profiling data from over 30,000 cancer patients to create targeted therapeutics that address the lack of effective drugs in precision oncology. Their approach enables more efficient clinical trials with significantly reduced enrollment and costs, while increasing the likelihood of FDA approval.
Funding
Funding not disclosed
Founders
Product
Problem
A significant barrier to implementing precision medicine in oncology is the lack of targeted therapeutics that can address actionable gene mutations or target gene expression identified through tumor profiling. Current drug development often focuses on identifying patients likely to respond to existing therapies, rather than designing new therapies based on patient data to address treatment gaps.
Solution
Aclys Bio develops precision antibodies optimized for precision oncology by leveraging molecular profiling data from tens of thousands of cancer patients. Their approach involves using computational methods and rational design to select targets, followed by antibody discovery and optimization using a proprietary mammalian cell-based platform. The resulting therapeutics are designed for greater efficacy and safety, enabling smaller, more efficient clinical trials and a faster path to market. Aclys Bio also partners with drug developers to maximize the impact of their pipeline.
Target Audience
Aclys Bio's primary customers are drug developers and pharmaceutical companies focused on precision oncology and seeking to expand their pipeline of targeted therapeutics.
Features
- Target selection informed by tumor profiles of over 30,000 cancer patients
- Proprietary mammalian cell-based discovery and optimization platform for high-quality antibodies
- Fully integrated high-speed antibody expression and proof-of-concept assays
- In vitro and in vivo evaluation for preclinical validation